Gene therapy hereditary diseases
Genotarget develops and implements genotherapeutic drugs
for the treatment of orphan neuromuscular diseases
for the treatment of orphan neuromuscular diseases
Pipeline
GT FP 100
LGMD R9
GENE FKRP
GT CN 100
Caltinopathy
LGMD R1
GENE CAPN3
GT DF 100
Dysferlinopathy
LGMD R2
GENE DYSF
Development
ДКИ
КИ
Access to the market
"LLC" Genotarget - resident of the "Biomed" cluster of the Skolkovo Foundation
The research is carried out with grant support from the Skolkovo Foundation
Skolkovo
Contact
Moscow, 121614
st. Krylatskie Hills, 32 bldg. 2,
room 4/1, room. 6, office 14
st. Krylatskie Hills, 32 bldg. 2,
room 4/1, room. 6, office 14
mail@genotarget.com
